

Philipp M Roessner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/986589/publications.pdf>

Version: 2024-02-01

16
papers

420
citations

840119

11
h-index

940134

16
g-index

19
all docs

19
docs citations

19
times ranked

558
citing authors

#	ARTICLE	IF	CITATIONS
1	T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?. <i>Leukemia</i> , 2020, 34, 2012-2024.	3.3	70
2	Interleukin-10 receptor signaling promotes the maintenance of a PD-1 ^{int} TCF-1 ⁺ CD8 ⁺ T ^h cell population that sustains anti-tumor immunity. <i>Immunity</i> , 2021, 54, 2825-2841.e10.	6.6	57
3	Control of chronic lymphocytic leukemia development by clonally-expanded CD8 ⁺ T-cells that undergo functional exhaustion in secondary lymphoid tissues. <i>Leukemia</i> , 2019, 33, 625-637.	3.3	55
4	PI3K γ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019, 33, 1427-1438.	3.3	51
5	EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4 ⁺ T cells in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 2311-2324.	3.3	27
6	Combining ibrutinib and checkpoint blockade improves CD8 ⁺ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice. <i>Haematologica</i> , 2021, 106, 968-977.	1.7	26
7	EOMES is essential for antitumor activity of CD8 ⁺ T cells in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 3152-3162.	3.3	26
8	CD8 ⁺ T-cells of CLL-bearing mice acquire a transcriptional program of T-cell activation and exhaustion. <i>Leukemia and Lymphoma</i> , 2020, 61, 351-356.	0.6	17
9	Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia. <i>Blood</i> , 2022, 139, 859-875.	0.6	16
10	Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL. <i>Genome Medicine</i> , 2020, 12, 29.	3.6	15
11	Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?. <i>Frontiers in Immunology</i> , 2020, 11, 595818.	2.2	13
12	Rejection of adoptively transferred E μ -TCL1 chronic lymphocytic leukemia cells in C57BL/6 substrains or knockout mouse lines. <i>Leukemia</i> , 2019, 33, 1514-1539.	3.3	12
13	TBET ^{hi} expressing Th1 CD4 ⁺ T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in E μ -TCL1 mice. <i>British Journal of Haematology</i> , 2020, 189, 133-145.	1.2	11
14	IDO1-Targeted Therapy Does Not Control Disease Development in the E μ -TCL1 Mouse Model of Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 1899.	1.7	9
15	An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies. <i>Blood Advances</i> , 2021, 5, 5060-5071.	2.5	9
16	Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients. <i>Leukemia</i> , 2021, , .	3.3	3